Ohio State Navbar

The Ohio State UniversityOffice of International Affairs

give a donation

Comparative exosome proteome profiling of high-grade serous ovarian cancer cells with their precursor cells identifies signaling pathways for targeted therapy

Research Scholar

Kalpana Deepa Priya Dorayappan, assistant professor (guest faculty), University of Madras (India)
Selvendiran Karuppaiyah, faculty mentor


  • Hometown: Kerala, India
  • Degrees received: Master of Science, M.Phil and PhD in biochemistry, University of Madras, India.

What is the issue or problem addresses in your research?

High-grade serous ovarian carcinoma (HGSOC) is an aggressive disease with a poor prognosis due to lack of early detection and chemotherapy resistance. To date, there are no highly specific serum biomarkers to aid in the early detection of HGSOC. Tumor cells release proteins through shed vesicles (exosomes) that were detected using a high throughput mass spectrometry to improve the specificity and sensitivity as biomarkers and associated signaling pathways help to develop targeted therapies.

What methodology did you use in your research?

We have utilized a novel in-house developed microfluidics based device to isolate exosomes from biologic specimens. Using Mass Spectrometry, we identified differentially expressed and statistically significant proteins between cancer cell and normal cell exosomes. We have used Ingenuity Pathway Analysis software to evaluate the signaling pathways that these proteins are involved in. This affords us the ability to make new discoveries for exosome-based biomarkers and targeted therapies.

What are the purpose/rationale and implications of your research?

Obtaining a relatively pure exosome population determines the success or failure within the field of exosome research. We hypothesize that our novel in-house developed microfluidics technology will allow us to make new discoveries in exosome-based biomarkers for the early detection of HGSOC, as well as to identify targets in the signaling pathways that will lead to more targeted therapies for patients with ovarian cancer.